Last reviewed · How we verify
MLC 901
At a glance
| Generic name | MLC 901 |
|---|---|
| Also known as | Nueroaid II |
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Alzheimer's Disease THErapy With NEuroaid II (PHASE3)
- Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (PHASE4)
- MLC901 in Moderate Traumatic Brain Injury (PHASE4)
- NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury (PHASE3)
- NeuroAiD Safe Treatment Registry
- MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial (EARLY_PHASE1)
- MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code) (PHASE4)
- NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MLC 901 CI brief — competitive landscape report
- MLC 901 updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI